Skip to main content

Amgen UPLIZNA revenue

  • AMGN · Nasdaq
  • Biotechnology
  • S&P 500
$465.67−0.30%Close 13 Nov 2026 · Market value $253.3B

UPLIZNA revenue at Amgen came to $451.0M for the quarter to 30 Sep 2026, up 191.0% from a year earlier.

As Amgen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 4 Nov 2026.

By quarter

$91.0MMar 2025$176.0MJun 2025$155.0MSep 2025$262.0MMar 2026$335.0MJun 2026$451.0MSep 2026
Amgen UPLIZNA revenue, every reported period
Period endingUPLIZNA revenueChange on a yearFiled
30 Sep 2026$451.0Mup 191.0%4 Nov 2026
30 Jun 2026$335.0Mup 90.3%5 Aug 2026
31 Mar 2026$262.0Mup 187.9%1 May 2026
30 Sep 2025$155.0M—5 Nov 2025
30 Jun 2025$176.0M—6 Aug 2025
31 Mar 2025$91.0M—2 May 2025

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Amgen: Product sales · Repatha revenue · EVENITY revenue · Prolia revenue · ENBREL revenue · TEZSPIRE revenue · TEPEZZA revenue · BLINCYTO revenue · Otezla revenue · Nplate revenue · KRYSTEXXA revenue · IMDELLTRA/IMDYLLTRA revenue · Vectibix revenue · KYPROLIS revenue · Aranesp revenue · XGEVA revenue · United States revenue · ROW revenue · financial statements

Every KPI and segment of AMGN, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.